Archive for April, 2017

The Winner of Tech’s Biggest Rivalry Could Be You

4 | By Michael A. Robinson

It’s about to become one of the biggest tech rivalries of all time.

We’re talking bigger than AMD vs. Intel, Netflix vs. Comcast, and Apple’s iOS vs. Alphabet’s Android.

That’s because this growing showdown is taking place over the Internet of Everything (IoE).

There’s a lot riding on the line here. Over the next two decades, the IoE will have a business and economic impact worth between $14 trillion and $25 trillion.

See, the IoE will connects trillions of sensors around the world that will be attached to everything from autos and streetlights to shipping boxes and robots to smart cities and homes.

That’s why the General Electric Co. (NYSE: GE) and Siemens AG (OTC: SIEGY) are fighting so hard to dominate this budding field.

One of the two stands to profit hugely.

And so do you.

One Small Company Leads This $25 Billion “Frontier” Market

1 | By Michael A. Robinson

Most established cancer treatments – from chemotherapy and radiation to the 200 drugs out there — have one thing in common.

They’re all more or less “one size fits all” treatments, procedures, or regimens.

But the most exciting, promising discoveries – and biggest profits – are made on the frontier. And on the frontier of cancer research is a treatment under development that’s going to disrupt the field for the next several decades.

I’m talking about powerful “bespoke” cancer treatments for every patient, using their own bodies to boot.

Not only will this improve and save lives, but it’ll also crack open a market worth $25 billion by 2025. It really is a revolutionary development.

But the “Buy” call I’m making today is still trading at “pre-revolutionary” prices…

While Others Worry, You Can Profit

4 | By Michael A. Robinson

As the song goes, “You can’t always get what you want.”

This applies well to last week’s announcement of plans for full legalization of adult marijuana use in Canada. During that April 13 event, the Trudeau government said all will be in place by July 1, 2018.

But there was a “problem” – at least according to some legalization advocates and analysts.

Instead of laying everything out precisely, legalization in Canada is still evolving. For instance, individual Canadian provinces will have a lot of say about where and when marijuana can be sold, how old buyers can be, and taxation.

So there is much more work to do than was hinted by the government when it leaked preliminary legalization details back on March 27.

And out come the handwringers – fretting that legalization will be delayed or… maybe… never even happen.

Don’t join these worrywarts.

Nothing here shatters the lucrative reality that double-, triple, or even quadruple-digit gains are on the way for the five stocks I included my latest report – How to Make a Fast Fortune on Canada’s Upcoming Total Legalization of Marijuana.

In fact, there are four reasons why you don’t need to lose sleep.

Here they are…

Sometimes the Road to Wealth Is Paved by Tech – and Toothpaste

1 | By Michael A. Robinson

Even if your name is Bill Gates or Warren Buffet, $3 billion is a lot of money.

And even if you’re finding that the years fly by as you get older, 12 years is a long time.

Yet, on average, that’s what it takes for a biopharmaceutical company to develop a new drug from discovery stage to pharmacy shelves.

Moreover, the ratio of researched treatments to eventually approved therapies – at somewhere between 5,000-to-1 and 10,000-to-1 – may be even more depressing for drug developers.

However, if all goes as planned – if a drug makes it into your medicine cabinet – then they’ll make that money back… and more. Particularly if they come up with a real blockbuster.

But still, so much vital R&D money goes down the drain.

Little wonder then that a major drug player might want to realign its operations to be less focused on the boom-and bust cycle of drug research.

Today, we’ll explore a Big Pharma leader that’s doing just that.

It got started on this move three years ago.

It just made a big promotion that will serve as a further catalyst in this same direction.

And its stock could make you 20% a year – or more – for a long time to come.

Read on…

When Putting Money on the Line, There’s One Thing Worse Than “Fake News”

0 | By Michael A. Robinson

Ever since Donald Trump was sworn in as president, we’ve seen a lot of talk about “fake news.”

Depending on how you’re feeling on any given day, that’s either hoaxes, propaganda, and disinformation that isn’t true… or simply news you don’t like.

But there’s something else going on – in the world of investing – that’s even more dangerous.

I call it “incomplete news.”

See, the mainstream financial media would have you think that blindly following Wall Street’s march will put you on the road to wealth.

In reality, that’s a path to ho-hum returns.

You can do better.

Much better.

And I can prove it…

These Two Triggers Are About to Create Fast Fortunes for Cannabis Investors

2 | By Michael A. Robinson

Last week, I showed you just how profitable “frontier investing” can be.

It’s a deceptively simple, powerful approach I use to help my Nova-X Report readers make fast fortunes: Research a good investment, build a thesis, target the best stock before Wall Street analysts know it exists, and let the profits come to you as the crowd piles in.

Silicon Valley is a hotbed of this kind of investing – one where my readers have been able to make a killing. Biotech, rare earths, and cryptocurrencies are three others.

Cannabis investing is the latest and most profitable.

It’s easier now than it’s ever been to get wired into the growth of the legal marijuana sector.

And even after the sweep of states legalizing cannabis on Nov. 8, there’s plenty more of that growth on the way.

Today we’ll look at why that’s true.

And how you can get in on it…

What This Federal “Task Force” Means for Cannabis Investors

0 | By Michael A. Robinson

Sometimes it feels like panic is our new national pastime.

Smart investors like you, however, know better than to jerk their knee every time the mainstream media sensationalizes a story.

That said, I subscribe to the theory that an occasional reminder can be helpful.

Why I’m a Huge Fan of “Frontier Investing” in Pot Stocks

1 | By Michael A. Robinson

When most investors think of the booming legal cannabis sector, they don’t automatically think “high tech” or the life sciences.

That’s a mistake – a potentially costly one.

For one thing, cannabinoids can be used to treat all sorts of ailments, from cancer to arthritis to insomnia. Then there are all the high-tech applications exploding in the growth and consumption of legal marijuana.

But more importantly, cannabis investing is out on the “frontier.”

As you’ll see, that’s one of the most profitable places you can be…

Legal Cannabis’ Credibility Soars With Launch of First “Pot Stock” ETF

1 | By Michael A. Robinson

We’ve been looking at legal marijuana stocks a lot lately.

If you need a reminder as to why, well, look at this…

In 2013, the market for medically “sanctioned’ marijuana was worth about $1.5 billion. It’s expected to reach $6.7 billion this year – and $35 billion by 2020. And by 2029: The market is projected to reach $100 billion.

Those are hefty numbers.

Marijuana Millions’ Northern Frontier Is Primed for Business

0 | By Michael A. Robinson

The hottest sector in the stock market is about to have one of those special “flashpoint” days.

As you know, legal marijuana is already booming in the 28 U.S. states where recreational and/or medical cannabis is legal.

Now comes the first major countrywide, full legalization of weed… in Canada.